Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy.
Journal: bioRxiv : the preprint server for biology
Published: February 20, 2025
Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.
Journal: British journal of haematology
Published: December 09, 2024
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Journal: Cancer immunology research
Published: June 05, 2024
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
Journal: Advances in therapy
Published: April 07, 2023
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Journal: Leukemia research
Published: January 25, 2023
Characterizing the exposure-response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 03, 2022
Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial.
Journal: Leukemia research
Published: May 09, 2022
Last Updated: 09/26/2026